To understand if MAGE-A3 antigen-specific TCRs discovered in our study is predictive for ICB immunotherapy outcome, we compared the TCR repertoires of 46 lung cancer treated with three rounds of nivolumab 48 with the TCR clonotypes derived from the MAGE-A3-Mp4 antigen-specific CD8+ T cell scTCR-seq data, and in particular, the 5 candidate TCRs deemed suitable for TCR-T cell design (Figure 8A). The gene discussed is CD8A; the disease is lung cancer.